Robert Brenner
Immunology and Microbiology · Indiana University
Publications
310
Citations
14,176
Est. group size
—
Recurring co-author estimate
Active years
61
Publishing since 1966
The recent publication record centers on clinical trials of atacicept, a therapy for IgA nephropathy and other autoimmune-related kidney (glomerular) diseases, alongside earlier work on ion channels and neuropharmacology in models of traumatic brain injury. The work spans drug development for immune-mediated diseases and studies of how various compounds affect ion channels and neural receptors. Note that the listed publications appear to mix contributions across multiple distinct topic areas.
Publication activity has been steady at a few papers per year for most of the decade, with a notable increase in 2024-2025.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- WCN26-6572 ORIGIN 3: A PHASE 3 TRIAL OF ATACICEPT IN IgA NEPHROPATHY
Kidney International Reports · 2026
- WCN26-6783 ORIGIN EXTEND: A LONG-TERM EXTENSION STUDY OF ATACICEPT IN IgA NEPHROPATHY
Kidney International Reports · 2026
- WCN26-6668 PIONEER: A BASKET TRIAL OF ATACICEPT IN AUTOIMMUNE-MEDIATED GLOMERULAR DISEASE
Kidney International Reports · 2026
- A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
New England Journal of Medicine · 2025
- #2859 <b>ORIGIN 2b: changes in Gd-IgA1 and eGFR after discontinuation of atacicept treatment in IgA nephropathy</b>
Nephrology Dialysis Transplantation · 2025
- WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
Kidney International Reports · 2025
- WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
Kidney International Reports · 2025
- #2936 Origin 3 study design: a global, randomized, controlled, Phase 3 study of atacicept in IgA nephropathy
Nephrology Dialysis Transplantation · 2025
- ORIGIN 3: A Phase 3 Trial of Atacicept in IgAN
Journal of the American Society of Nephrology · 2025
- Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Journal of the American Society of Nephrology · 2024
- Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN)
Journal of the American Society of Nephrology · 2024
- Acute Treatment with the M-Channel (Kv7, KCNQ) Opener Retigabine Reduces the Long-Term Effects of Repetitive Blast Traumatic Brain Injuries
Neurotherapeutics · 2023
- Propriété et progrès : quand Adam Smith faisait fausse route
ENS Éditions eBooks · 2023
- Effects of Sublethal Organophosphate Toxicity and Anti-cholinergics on Electroencephalogram and Respiratory Mechanics in Mice
Frontiers in Neuroscience · 2022
- Dequalinium chloride is an antagonists of α7 nicotinic acetylcholine receptors
European Journal of Pharmacology · 2022
- Kidney International Reports×5
- Journal of the American Society of Nephrology×4
- Journal of Neurophysiology×2
- Neurotherapeutics×2
- Nephrology Dialysis Transplantation×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile